Phase 3 multicentre, open, parallel, prospective, randomized comparative clinical study of Dulaglutide Injection (BA5101) in Chinese adults with type 2 diabetes

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dulaglutide (Primary)
Indications Type 2 diabetes mellitus
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Sponsors Shandong Boan Biotechnology

28 May 2024 According to a Luye Pharma Group media release,the company has announced that the Center for Drug Evaluation (CDE) of Chinas National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for its Dulaglutide Injection (BA5101), a drug for glycemic control in adults with type 2 diabetes.
15 May 2023 Status changed from recruiting to active, no longer recruiting according to Luye Pharma Group media release.
22 Jul 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com